DIHYDROFOLATE-REDUCTASE FROM THE PATHOGENIC FUNGUS PNEUMOCYSTIS-CARINII - CATALYTIC PROPERTIES AND INTERACTION WITH ANTIFOLATES

被引:36
作者
MARGOSIAK, SA
APPLEMAN, JR
SANTI, DV
BLAKLEY, RL
机构
[1] ST JUDE CHILDRENS RES HOSP, DEPT MOLEC PHARMACOL, MEMPHIS, TN 38101 USA
[2] UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA
[3] UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA
关键词
D O I
10.1006/abbi.1993.1453
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dihydrofolate reductase (DHFR) from the fungus Pneumocystis carinii (pcDHFR), a target for antifolate inhibitors, has been compared with host enzyme, human DHFR (hDHFR), and with DHFR from Escherichia coli. Among the results of the considerable structural differences between pcDHFR and the other two enzymes is a much higher turnover number (k(cat), 136 s-1) for pcDHFR. This is due to rapid hydride transfer from NADPH to dihydrofolate (rate constant 402 s-1), very rapid dissociation of NADP from the product complex (rate constant, k(off), >1000 s-1), and after NADPH binding, rapid dissociation of tetrahydrofolate (k(off), 216 s-1). Cycling of pcDHFR is almost exclusively by this pathway. The high k(cat) contributes to a high K(m) for NADPH (9 μM) and an unusually high K(m) for dihydrofolate (2.5 μM). Nevertheless, the efficiency of pcDHFR is greater than DHFR from E. coli and about 25% that of hDHFR. Of seven clinically relevant inhibitors investigated, only one (trimethoprim) had a slightly lower K(i) for pcDHFR than for hDHFR. The therapeutic value of trimethoprim-sulfa treatment of P. carinii infections indicates that other factors play an important role, but the results are consistent with the frequency of complications due to toxicity of trimethoprim. © 1993 Academic Press, Inc.
引用
收藏
页码:499 / 508
页数:10
相关论文
共 41 条
[21]   RIBOSOMAL-RNA SEQUENCE SHOWS PNEUMOCYSTIS-CARINII TO BE A MEMBER OF THE FUNGI [J].
EDMAN, JC ;
KOVACS, JA ;
MASUR, H ;
SANTI, DV ;
ELWOOD, HJ ;
SOGIN, ML .
NATURE, 1988, 334 (6182) :519-522
[22]   ISOLATION AND EXPRESSION OF THE PNEUMOCYSTIS-CARINII DIHYDROFOLATE-REDUCTASE GENE [J].
EDMAN, JC ;
EDMAN, U ;
CAO, M ;
LUNDGREN, B ;
KOVACS, JA ;
SANTI, DV .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (22) :8625-8629
[23]   CONSTRUCTION AND EVALUATION OF THE KINETIC SCHEME ASSOCIATED WITH DIHYDROFOLATE-REDUCTASE FROM ESCHERICHIA-COLI [J].
FIERKE, CA ;
JOHNSON, KA ;
BENKOVIC, SJ .
BIOCHEMISTRY, 1987, 26 (13) :4085-4092
[24]   VARIATION OF TRANSITION-STATE STRUCTURE AS A FUNCTION OF THE NUCLEOTIDE IN REACTIONS CATALYZED BY DEHYDROGENASES .2. FORMATE DEHYDROGENASE [J].
HERMES, JD ;
MORRICAL, SW ;
OLEARY, MH ;
CLELAND, WW .
BIOCHEMISTRY, 1984, 23 (23) :5479-5488
[25]   NEW METHOD FOR DERIVING STEADY-STATE RATE EQUATIONS SUITABLE FOR MANUAL OR COMPUTER USE [J].
INDGE, KJ ;
CHILDS, RE .
BIOCHEMICAL JOURNAL, 1976, 155 (03) :567-570
[26]  
Johnson K. A., 1992, ENZYMES, P1, DOI DOI 10.1016/S1874-6047(08)60019-0
[27]   PNEUMOCYSTIS-CARINII PNEUMONIA - THERAPY AND PROPHYLAXIS [J].
KOVACS, JA ;
MASUR, H .
JOURNAL OF INFECTIOUS DISEASES, 1988, 158 (01) :254-259
[28]   CHARACTERIZATION OF DIHYDROFOLATE-REDUCTASE OF PNEUMOCYSTIS-CARINII AND TOXOPLASMA-GONDII [J].
KOVACS, JA ;
ALLEGRA, CJ ;
MASUR, H .
EXPERIMENTAL PARASITOLOGY, 1990, 71 (01) :60-68
[29]   PNEUMOCYSTIS-CARINII PNEUMONIA - A COMPARISON BETWEEN PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME AND PATIENTS WITH OTHER IMMUNODEFICIENCIES [J].
KOVACS, JA ;
HIEMENZ, JW ;
MACHER, AM ;
STOVER, D ;
MURRAY, HW ;
SHELHAMER, J ;
LANE, HC ;
URMACHER, C ;
HONIG, C ;
LONGO, DL ;
PARKER, MM ;
NATANSON, C ;
PARRILLO, JE ;
FAUCI, AS ;
PIZZO, PA ;
MASUR, H .
ANNALS OF INTERNAL MEDICINE, 1984, 100 (05) :663-671
[30]   POTENT ANTIPNEUMOCYSTIS AND ANTITOXOPLASMA ACTIVITIES OF PIRITREXIM, A LIPID-SOLUBLE ANTIFOLATE [J].
KOVACS, JA ;
ALLEGRA, CJ ;
SWAN, JC ;
DRAKE, JC ;
PARRILLO, JE ;
CHABNER, BA ;
MASUR, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (04) :430-433